Interstitial cystitis/bladder pain syndrome
Drug research and approvals for interstitial cystitis/bladder pain syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 22 studies of interstitial cystitis/bladder pain syndrome are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 22
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
- Aerobic Exercise and Connective Tissue Massage in Painful Bladder SyndromeNCT07839689 · Not applicable · Hacettepe University · starts Apr 30, 2026
- The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's…NCT07459790 · Phase 2 / Phase 3 · JSC NextGen · starts Dec 29, 2023
- The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's…NCT07391306 · Phase 2 / Phase 3 · JSC NextGen · starts Feb 16, 2024
- Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in…NCT06729151 · Not reported · Walter Reed National Military Medical Center · starts Nov 1, 2024
- Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical InstillationNCT06719232 · Not reported · Jahn Ferenc South Pest Teaching Hospital · starts Oct 1, 2024
- Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain…NCT06394830 · Phase 2 · Vaneltix Pharma, Inc. · starts Dec 13, 2024
- Bladder Botox UTI Antibiotic ProphylaxisNCT06387329 · Phase 4 · Walter Reed National Military Medical Center · starts Apr 4, 2024
- Acupuncture First for IC/BPSNCT06366269 · Not applicable · University Hospitals Cleveland Medical Center · starts Jan 21, 2025
- Pain Type and Interstitial Cystitis/Bladder Pain Syndrome TreatmentNCT06299683 · Not applicable · Vanderbilt University Medical Center · starts May 1, 2024
| Feb 25, 2022 | A multicenter, randomized, double-blind, placebo-controlled, parallel arm study to assess the safety and efficacy of a single treatment of botox®, followed by…Botox | AbbVie | Closed |
| Jul 3, 2020 | Efficacy and safety of fremanezumab for treatment of female patients with ic-bpsAjovy (fremanezumab) | Teva Pharmaceutical Industries | Pending |
| Jul 29, 2016 | The leadership 301 trial: a 12-week, randomized, multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy…AQX-1125 | Aquinox Pharmaceuticals Inc | Closed |
| Jun 18, 2015 | A multicenter, randomized, double-blind, placebo-controlled study, evaluating safety and efficacy of liris® 400 mg in females with interstitial…Liris | AbbVie | Closed |
| May 14, 2015 | A multicenter, randomized, double-blind, placebo-controlled study, evaluating safety and efficacy of liris® 400 mg in females with interstitial cystitis with…Liris | AbbVie | Closed |
| May 30, 2013 | The leadership study: a phase II study to evaluate the efficacy and safety of AQX-1125 in subjects with interstitial cystitis/bladder pain syndrome mediated by…AQX-1125 | Aquinox Pharmaceuticals Inc | Ongoing |
| Apr 10, 2013 | A phase 2a multicenter, randomized, double-blinded, placebo-controlled study evaluating safety, tolerability and efficacy of liris® 400 mg in women with…Liris | Taris Biomedical Inc | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA